Vantive Brand Guidelines: Baxter’s Kidney Care Unit, Sold to Carlyle in 2025

Seven decades inside Baxter.

Vantive is new as a name but old as a business. It is the former kidney-care segment of Baxter International, the Deerfield, Illinois, healthcare company founded in 1931 by Donald Baxter, a Los Angeles doctor, as a maker of intravenous solutions, English Wikipedia says. Vantive dates its own line to 1956, when, it says, Baxter produced the first commercial dialysis system, building on the work of the Dutch physician Willem Kolff, whose first “artificial kidney” was made from wood slats, orange-juice cans and a cellophane membrane.

The timeline on Vantive’s website runs on through home therapy. It says Baxter introduced the first peritoneal dialysis solution in 1960, a therapy in which the blood is filtered through the body’s own peritoneal membrane rather than an external dialyzer, and brought the first CAPD system, for continuous ambulatory peritoneal dialysis, to the United States in 1979. In 1994 it launched the Homechoice automated peritoneal dialysis system, for treatment at home, and opened a plant in Singapore to make dialysis solutions for Asian markets; in 2003 came Extraneal, a solution that is not based on glucose.

The largest single addition was Swedish. In 2013 Baxter bought Gambro, the Lund company founded in 1964 to make the artificial kidney of the professor Nils Alwall; English Wikipedia says European Union competition regulators approved the deal in July 2013 and that Baxter completed it that September. Gambro made products for kidney and liver dialysis and other treatments carried out outside the body, English Wikipedia says, with its largest factory at Hechingen in Germany. Gambro’s former clinic arm had been sold separately in 2007 and now trades as Diaverum, an unrelated company.

From segment to standalone.

The separation was planned in public. Baxter announced its intention to create a standalone kidney-care company in January 2023 and said in March 2024 that it was exploring a possible sale, according to its own press release of 13 August 2024. MedTech Dive reported the same day that Baxter had first planned to spin the unit off as a separately listed company before switching to a sale. On 13 August 2024 Baxter and funds managed by the investment firm Carlyle announced a definitive agreement for Carlyle to buy the Kidney Care segment, “to be named Vantive.” Carlyle invested in partnership with Atmas Health, a group formed in 2022 by three medical-technology executives; its co-founder Kieran Gallahue was named chairman, and Chris Toth, who had run Kidney Care at Baxter, became chief executive.

The sale closed on 31 January 2025, Baxter said in its quarterly report for the first three months of 2025. When the agreement was signed, the business had more than 23,000 employees and offered products for peritoneal dialysis, hemodialysis and organ-support therapies, including continuous renal replacement therapy, Baxter said. Vantive’s website now calls it “a vital organ therapy company” that “separated from Baxter in 2025,” and names Vantive Health LLC as the holder of its trademarks.

Its signature systems span the home and the hospital. Vantive says it launched Amia with Sharesource in 2015, an automated peritoneal dialysis system that keeps patients remotely connected with their care teams; the Theranova dialyzer in 2016, for what it calls expanded hemodialysis, or HDx; and, in 2018, the Kaguya system for Japan and the PrisMax system for continuous renal replacement therapy and other organ-support treatments in intensive care. Its website carries the line “Extending Lives and Expanding Possibilities.”

Design and documentation.

Dialysis and kidney-care companies sell to two audiences at once. One is clinical: nephrologists, nurses, technicians and hospital buyers who choose machines, dialyzers and solutions. The other is the patient, who may spend several sessions a week in a treatment chair or carry out dialysis at home. Their imagery tends to answer both: a calm patient in a reclining chair beside a machine, a nurse in a bright, orderly clinic, and close-ups of dialyzers, tubing and the screens of haemodialysis machines.

Home treatment has added a second setting. Peritoneal dialysis and home haemodialysis bring the equipment into kitchens, bedrooms and living rooms, and the companies that make or support it often show machines beside sofas and tables rather than in clinical rooms. Symbols tend to stay simple: kidney shapes, drops, waves and circles that print clearly on a label, a machine housing or a clinic sign.

The trade meets at a few large congresses. The American Society of Nephrology’s Kidney Week, held in Denver in 2026, drew nearly 12,000 participants from close to 100 countries, the society says, and makers such as Fresenius Medical Care list it among their events. In Europe, the European Renal Association holds an annual congress, scheduled for Rotterdam in 2027 and Berlin in 2028, according to the association.

This guide sets out what can be checked about each company: who founded it, who owns it, where it works and what it makes. Where a fact rests only on a company’s own word, we say so, and the colours and typefaces shown are our own interpretation rather than any official brand standard.

A narrower focus, announced in 2026.

The company is still reshaping itself. On 3 November 2026 Vantive announced a definitive agreement to sell the majority of its hemodialysis business to Rockwell Medical, a Nasdaq-listed maker of hemodialysis products. The sale covers Vantive’s hemodialysis concentrates, HD monitors and water treatment systems, with related consumables and technical services. It was agreed in November 2026 and had not been completed at the time of writing: Vantive said it expected the deal to close in mid-2027, subject to regulatory approvals and other conditions. On completion, ownership of Vantive’s factory at Medolla, in Italy, is to pass to Rockwell Medical. The dialyzers, including Theranova, are not part of the sale.

Vantive presented the move as a sharper focus on two settings: dialysis at home, and organ support in the intensive care unit, with a portfolio it describes as centred on chronic disease management and critical care. The same release says its people, products and services account for more than a million “touchpoints” with patients every day around the world, and that it plans to look beyond kidney care to other vital-organ therapies.

For a design guide, Vantive shows how a carve-out has to build a company brand from nothing around products that already carry long histories and names of their own. Compare Baxter, the parent it left in 2025, and Diaverum, which grew out of the Gambro business that Baxter later bought. For this guide we use a deep plum, a soft lilac and a fresh green with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Vantive’s identity on hand — save it to a board in the Made Good inspiration library.